Randomized Study of Human Parathyroid Hormone in Middle-Aged Men With Idiopathic Osteoporosis
I. Determine the effect of human parathyroid hormone (1-34) on bone mass in middle-aged men with idiopathic osteoporosis.
|Study Design:||Allocation: Randomized
Primary Purpose: Treatment
|Study Start Date:||October 1999|
|Estimated Study Completion Date:||July 2004|
PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled study. All patients self-administer daily subcutaneous injections of human parathyroid hormone (1-34) or placebo for a period of 2.5 years.
Patients are followed regularly for unacceptable toxicities.
Completion date provided represents the completion date of the grant per OOPD records
Please refer to this study by its ClinicalTrials.gov identifier: NCT00004406
|United States, New York|
|Columbia University College of Physicians and Surgeons|
|New York, New York, United States, 10032|
|Study Chair:||John Paul Bilezikian||Columbia University|